Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19
- PMID: 34774194
- PMCID: PMC8584820
- DOI: 10.1016/S0140-6736(21)02014-6
Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19
Comment on
-
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.Lancet. 2021 Dec 11;398(10317):2173-2184. doi: 10.1016/S0140-6736(21)02000-6. Epub 2021 Nov 11. Lancet. 2021. PMID: 34774196 Free PMC article. Clinical Trial.
References
-
- Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021 doi: 10.1016/S0140-6736(21)02000-6. published online Nov 11. - DOI - PMC - PubMed
-
- Yadav PD, Sapkal GN, Ella R, et al. Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152. bioRxiv. 2021 doi: 10.1101/2021.06.05.447177. published online June 7. (preprint). - DOI
-
- WHO WHO issues emergency use listing for eighth COVID-19 vaccine. Nov 3, 2021. https://www.who.int/news/item/03-11-2021-who-issues-emergency-use-listin...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
